Johnson & Johnson $JNJ Shares Sold by Barlow Wealth Partners Inc.

Barlow Wealth Partners Inc. decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 0.5% in the 2nd quarter, HoldingsChannel reports. The firm owned 25,599 shares of the company’s stock after selling 135 shares during the quarter. Barlow Wealth Partners Inc.’s holdings in Johnson & Johnson were worth $3,982,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Werba Rubin Papier Wealth Management boosted its stake in shares of Johnson & Johnson by 19.5% in the second quarter. Werba Rubin Papier Wealth Management now owns 2,892 shares of the company’s stock valued at $442,000 after purchasing an additional 471 shares during the period. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at approximately $1,224,000. WealthPlan Investment Management LLC boosted its stake in shares of Johnson & Johnson by 20.2% in the second quarter. WealthPlan Investment Management LLC now owns 70,070 shares of the company’s stock valued at $10,703,000 after purchasing an additional 11,759 shares during the period. Bridges Investment Management Inc. boosted its stake in shares of Johnson & Johnson by 4.4% in the second quarter. Bridges Investment Management Inc. now owns 77,996 shares of the company’s stock valued at $11,914,000 after purchasing an additional 3,298 shares during the period. Finally, Uptick Partners LLC grew its position in shares of Johnson & Johnson by 34.4% during the second quarter. Uptick Partners LLC now owns 4,065 shares of the company’s stock worth $621,000 after buying an additional 1,040 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on JNJ. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. The Goldman Sachs Group boosted their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Royal Bank Of Canada reissued an “outperform” rating and set a $209.00 price objective on shares of Johnson & Johnson in a research report on Friday, October 10th. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the stock an “overweight” rating in a research report on Friday, October 3rd. Finally, Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $199.59.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $193.27 on Friday. The stock has a 50 day moving average price of $180.49 and a 200 day moving average price of $164.86. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $465.45 billion, a price-to-earnings ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.